Kurs
-2,89%
Likviditet
1,99 MSEK
Kalender
| Tid* | ||
| 2025-03-27 | N/A | Årsstämma |
| 2025-02-27 | N/A | Bokslutskommuniké 2024 |
| 2024-08-16 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-02 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2024-03-28 | - | Årsstämma |
| 2024-02-27 | - | Bokslutskommuniké 2023 |
| 2023-08-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-05 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2023-03-31 | - | Årsstämma |
| 2023-02-27 | - | Bokslutskommuniké 2022 |
| 2022-08-12 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-09 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2022-03-31 | - | Årsstämma |
| 2022-02-28 | - | Bokslutskommuniké 2021 |
| 2021-08-13 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-17 | - | Split NXTMS 100:1 |
| 2021-04-30 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2021-04-29 | - | Årsstämma |
| 2021-03-01 | - | Extra Bolagsstämma 2021 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-08-14 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-01 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-11 | - | Extra Bolagsstämma 2019 |
| 2019-08-16 | - | Kvartalsrapport 2019-Q2 |
| 2019-03-28 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2019-03-26 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2019-03-25 | - | Årsstämma |
| 2019-03-04 | - | Bokslutskommuniké 2018 |
| 2018-11-26 | - | Split NXTMS 30:1 |
| 2018-11-21 | - | Extra Bolagsstämma 2018 |
| 2018-08-16 | - | Kvartalsrapport 2018-Q2 |
| 2018-03-29 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2018-03-28 | - | Årsstämma |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-08-16 | - | Kvartalsrapport 2017-Q2 |
| 2017-03-29 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2017-03-28 | - | Årsstämma |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2017-02-17 | - | Extra Bolagsstämma 2017 |
| 2016-08-17 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-01 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2016-03-31 | - | Årsstämma |
| 2016-02-29 | - | Bokslutskommuniké 2015 |
| 2015-12-22 | - | Extra Bolagsstämma 2015 |
| 2015-08-20 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-01 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2015-03-31 | - | Årsstämma |
| 2015-02-26 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Company Announcement, Helsinki, 30 December 2024 at 2:30 PM (EET)
Nexstim Plc’s Financial Information and Annual General Meeting in 2025
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it will publish the following financial information in 2025:
- The 2024 Financial Statements Release and Half-Yearly Report July−December 2024 (H2) on Thursday, February 27, 2025.
- Half-Yearly Report January-June 2025 (H1) on Friday, August 15, 2025.
Nexstim’s Annual Report 2024 will be published and available on the Company’s website on Thursday, March 6, 2025.
The Annual General Meeting is tentatively scheduled to be held on Thursday, March 27, 2025, at 10:00 am.
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
The Company’s Certified Advisor is Carnegie Investment Bank AB (publ).
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com